UroToday1d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: ‘EMBARK’ing on a Novel Treatment Paradigm
PSA <0.2 ng/mL: Treatment was suspended at week 37 and PSA was monitored with treatment reinitiated if PSA rose again PSA >0.2 ng/mL: Treatment was continued PSA progression (HR 0.07, 95% CI 0.03–0.14 ...
UroToday1d
Treatment Intensification for High-Risk Biochemically Recurrent M0 HSPC: EMBARK in the PSMA PET Era and Ongoing Trials
This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...
UroToday6d
Metastasis Development in Non-Muscle-Invasive Bladder Cancer - Beyond the Abstract
This review, published in Nature Urology Reviews, explores a relatively less common but dangerous entity of metastatic non-muscle-invasive bladder cancer (mNMIBC). This is a challenging condition ...
UroToday6d
European Continence Strategy Targets Escalating Costs and Inequalities in Incontinence Care - Philip van Kerrebroeck
European Continence Strategy Targets Escalating Costs and Inequalities in Incontinence Care - Philip van Kerrebroeck ...
UroToday6d
Exploring the Priorities of Older Adults in Managing Urinary Incontinence: a Patient-Oriented Research Approach.
Urinary incontinence (UI), the complaint of involuntary leakage of urine, has a substantial impact on the quality of life of older adults. Most UI research is driven by researchers and lacks the ...
UroToday6d
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men.
Historically, Asia had a lower prostate cancer (PCa) incidence and mortality compared with Western countries, but the gap is narrowing. Paradoxically, Asians have been reported to present with more ...
UroToday6d
Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.
To evaluate a cancer detecting artificial intelligence (AI) algorithm on serial biopsies in patients with prostate cancer on active surveillance (AS). A total of 180 patients in the Prostate Cancer ...
UroToday6d
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers.
Breast and prostate tumors are known to be less responsive to immune checkpoint inhibitors (ICIs). Tissue-based tumor mutation burden (tTMB) has emerged as a predictive biomarker of response to ICIs, ...
UroToday6d
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: An Updated Network Meta-analysis Including ARANOTE Data.
The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has been extended by another phase 3 randomized control trial (ARANOTE) demonstrating favorable outcomes of a doublet ...
UroToday6d
Virtual simulator for cystoscopy containing motion blur and bladder debris to aid the development of clinical tools.
Cystoscopic data can be used to improve bladder cancer care, but cystoscopic videos are cumbersome to review. Alternatively, cystoscopic video data can be preserved in the form of a 3D bladder ...
UroToday6d
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers.
Advances in molecular diagnostics have ushered in a new era for patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular modalities for the assessment of disease ...
UroToday6d
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer.
Advanced prostate cancer (PCa) is enriched for alterations in DNA damage repair genes; poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a class of drugs that have demonstrated effectiveness ...